Sanofi axes two more inflammatory-disease drugs
Why it matters: The decisions remove two externally sourced drugs from Sanofi’s immunology pipeline, days after the French…
Sanofi drops eczema drug from $1.1B Kymab deal
Why it matters: Amlitelimab was the principal asset behind Sanofi’s $1.1 billion acquisition of Cambridge, UK-based Kymab in…
Sanofi’s new COVID shot tops Moderna’s mNEXSPIKE in safety trial
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the…
Sanofi halts phase 3 autoimmune trial early over lackluster data
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely…
Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble
When Sanofi coughed up $11.6bn for rare diseases pharma Bioverativ in 2018, many commentators said the French firm…
Medidata’s Next-Gen AI Imaging Solution Delivers
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) — Medidata, a Dassault Systèmes brand and leading provider of clinical…